[
  {
    "ts": null,
    "headline": "Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC",
    "summary": "Nektar Therapeutics' REZPEG shows progress in treating atopic dermatitis & alopecia areata. Click here to find out why I rate NKTR stock a Buy.",
    "url": "https://finnhub.io/api/news?id=f128a1f729ecf86cd2aa7397420f8ebc49072db584942165e3499cb02c25eaaa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749654838,
      "headline": "Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC",
      "id": 135193286,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2218104602/image_2218104602.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Nektar Therapeutics' REZPEG shows progress in treating atopic dermatitis & alopecia areata. Click here to find out why I rate NKTR stock a Buy.",
      "url": "https://finnhub.io/api/news?id=f128a1f729ecf86cd2aa7397420f8ebc49072db584942165e3499cb02c25eaaa"
    }
  }
]